SCHEMBL31332883

SCHEMBL31332883

CCOC(=O)c1c(C)ncn1COC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 2/20 0.43
HPGD P15428 2/20 0.43
HSD17B10 Q99714 2/20 0.43
MAPK1 P28482 3/20 0.41
KMT2A Q03164 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
RECQL P46063 1/20 0.39
MAPK10 P53779 1/20 0.39
MAPT P10636 3/20 0.39
GAA P10253 1/20 0.39
POLB P06746 1/20 0.39
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA7 P43166 2/20 0.38
CA9 Q16790 2/20 0.38
CA14 Q9ULX7 2/20 0.38
ESR1 P03372 1/20 0.38
ESR2 Q92731 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24376040 0.85 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDHSD17B10MAPK1
SCHEMBL19798047 0.85 KMT2A (0.42) ALDH1A1KDM4EHPGDHSD17B10MAPK1
SCHEMBL4125342 0.81 TNF (0.40) ALDH1A1KDM4EHPGDHSD17B10MAPK1
SCHEMBL27349451 0.80 ALDH1A1 (0.38) ALDH1A1KDM4EHPGDHSD17B10MAPK1
SCHEMBL27094264 0.80 ALDH1A1 (0.38) ALDH1A1KDM4EHPGDHSD17B10MAPK1
SCHEMBL19797891 0.79 TGFBR1 (0.47) ALDH1A1KDM4EHPGDHSD17B10MAPK1
SCHEMBL20360622 0.78 LMNA (0.41) ALDH1A1KDM4EHPGDHSD17B10MAPK1
SCHEMBL5937208 0.77 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDHSD17B10MAPK1
SCHEMBL11213556 0.77 SMN1; SMN2 (0.55) ALDH1A1KDM4EMAPK1SMN1; SMN2RECQL
SCHEMBL5805582 0.76 KDM4E (0.46) ALDH1A1KDM4EHPGDHSD17B10MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709374-A2 KCC2 POTENTIATORS AND USES THEREOF Axonis Therapeutics, Inc. (US) 2026-03-18 EP disclosed
US-20260062402-A1 KCC2 POTENTIATORS AND USES THEREOF AXONIS THERAPEUTICS INC (US) 2026-03-05 US disclosed
WO-2024233885-A2 KCC2 POTENTIATORS AND USES THEREOF AXONIS THERAPEUTICS, INC. (US) 2024-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062402-A1 KCC2 POTENTIATORS AND USES THEREOF HCN2, HCN1, HCN4 ALDH1A1 2748/4885KDM4E 2478/4885HPGD 2024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.